Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Paragon 28 Inc (FNA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: FNA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -25.88% | Avg. Invested days 41 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.10B USD | Price to earnings Ratio - | 1Y Target Price 14.5 |
Price to earnings Ratio - | 1Y Target Price 14.5 | ||
Volume (30-day avg) 1801460 | Beta 1.54 | 52 Weeks Range 4.65 - 13.13 | Updated Date 04/1/2025 |
52 Weeks Range 4.65 - 13.13 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.66 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Earnings Date
Report Date 2025-03-07 | When - | Estimate -0.1 | Actual -0.1295 |
Profitability
Profit Margin -21.33% | Operating Margin (TTM) -8.97% |
Management Effectiveness
Return on Assets (TTM) -8.18% | Return on Equity (TTM) -36.39% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1172322658 | Price to Sales(TTM) 4.28 |
Enterprise Value 1172322658 | Price to Sales(TTM) 4.28 | ||
Enterprise Value to Revenue 4.58 | Enterprise Value to EBITDA -32.86 | Shares Outstanding 83937000 | Shares Floating 44186644 |
Shares Outstanding 83937000 | Shares Floating 44186644 | ||
Percent Insiders 31.21 | Percent Institutions 50.88 |
Analyst Ratings
Rating 4.57 | Target Price 14.33 | Buy 3 | Strong Buy 4 |
Buy 3 | Strong Buy 4 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Paragon 28 Inc
Company Overview
History and Background
Paragon 28, Inc. was founded in 2010 and is headquartered in Englewood, Colorado. It is a medical device company focused on the foot and ankle orthopedic market. They design, develop, manufacture, and market orthopedic implants and surgical instrumentation.
Core Business Areas
- Foot and Ankle Orthopedics: Paragon 28 focuses exclusively on solutions for foot and ankle conditions. Their product portfolio includes implants, instruments, and disposables used in various surgical procedures related to foot and ankle reconstruction, trauma, and sports medicine.
Leadership and Structure
The leadership team consists of experienced professionals in the medical device industry. The organizational structure typically involves departments for R&D, manufacturing, sales, marketing, and finance.
Top Products and Market Share
Key Offerings
- APEX 3D Total Ankle Replacement System: A total ankle replacement system designed to restore function and relieve pain. The market share is growing. Competitors: Stryker, Zimmer Biomet, Wright Medical (now part of Stryker).
- Silverback Ankle Fusion System: Implants and instrumentation for ankle fusion procedures. Market share is competitive. Competitors: Stryker, DePuy Synthes, Zimmer Biomet.
- Phantom Hindfoot Nail System: Implants for hindfoot fusion and fracture fixation. Market share is increasing. Competitors: Stryker, DePuy Synthes.
Market Dynamics
Industry Overview
The foot and ankle orthopedic market is driven by factors such as an aging population, increasing incidence of diabetes, and rising rates of sports-related injuries. It is a growing market with ongoing innovation in surgical techniques and implant technologies.
Positioning
Paragon 28 positions itself as a specialist in foot and ankle orthopedics, offering a comprehensive portfolio of products and focusing on innovation and surgeon education. Its competitive advantage lies in its specialization and focus on this specific area.
Total Addressable Market (TAM)
The total addressable market is estimated in the billions of dollars. Paragon 28 is positioned to capture a significant share of this market through its specialized product offerings and strong relationships with surgeons.
Upturn SWOT Analysis
Strengths
- Specialized focus on foot and ankle orthopedics
- Innovative product portfolio
- Strong relationships with surgeons
- Rapid revenue growth
Weaknesses
- Limited product diversification
- Smaller size compared to major orthopedic players
- Dependence on surgeon adoption of new products
Opportunities
- Expanding product offerings within foot and ankle
- Geographic expansion into international markets
- Acquisitions of complementary technologies or companies
- Increasing demand for minimally invasive surgical techniques
Threats
- Competition from larger orthopedic companies
- Pricing pressures from hospitals and payers
- Regulatory changes affecting medical device approvals
- Product liability risks
Competitors and Market Share
Key Competitors
- Stryker (SYK)
- DePuy Synthes (JNJ)
- Zimmer Biomet (ZBH)
Competitive Landscape
Paragon 28 competes with larger orthopedic companies that have broader product portfolios and greater financial resources. However, Paragon 28's specialization in foot and ankle orthopedics gives it a competitive advantage in this niche market.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Paragon 28 has experienced significant revenue growth in recent years due to increased product adoption and market penetration.
Future Projections: Analyst estimates generally project continued revenue growth for Paragon 28, driven by product innovation and market expansion.
Recent Initiatives: Recent initiatives include the launch of new products, expansion of sales teams, and strategic partnerships with key opinion leaders.
Summary
Paragon 28 is a focused player in the foot and ankle orthopedic market, exhibiting solid growth through its specialized product line and surgeon relationships. Its smaller size compared to major competitors is a challenge, but its niche focus and innovative approach provide a competitive edge. Continuous innovation and strategic partnerships will be vital for sustained success.
Similar Companies
- SYK
- ZBH
- JNJ
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Market Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market data and analyst estimates are subject to change. Conduct thorough research before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Paragon 28 Inc
Exchange NYSE | Headquaters Englewood, CO, United States | ||
IPO Launch date 2021-10-15 | Co-Founder, Chairman, President & CEO Mr. Albert DaCosta | ||
Sector Healthcare | Industry Medical Devices | Full time employees 525 | Website https://paragon28.com |
Full time employees 525 | Website https://paragon28.com | ||
Paragon 28, Inc. develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. The company offers forefoot systems, including gorilla precision MTP plating system, gorilla precision lapidus plating system, phantom lapidus intramedullary nail system, Bun-Yo-Matic lapidus clamp, and precision MIS screw system; and fracture fixation systems comprising gorilla ankle fracture plating system, baby gorilla plating system, monster screw system, monkey bars external fixation system, R3Flex syndesmotic repair system, and phantom fibula nail system. It also provides flatfoot systems, such as gorilla universal plating system, JAWS great white staple system, monster screw system, grappler suture anchor system, and mister tendon harvester system; ankle replacement system consists of metallic and plastic implant components, as well as ankle fusion plating system and phantom hindfoot nailing system; Charcot systems, including the joust beaming system, gorilla medial column plating system, and monkey rings external fixation system; and orthobiologics products, such as V92 cellular bone matrix, PRESERVE bone wedges, MgNum bone void filler, and BEAST demineralized bone matrix. The company serves hospitals, ambulatory surgery centers, and health care facilities through a network of sales representatives and stocking distributors. Paragon 28, Inc. was founded in 2010 and is headquartered in Englewood, Colorado.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.